SENP1 regulates PTEN stability to dictate prostate cancer development

Tasneem Bawa-Khalfe, Feng Ming Yang, Joan Ritho, Hui Kuan Lin, Jinke Cheng, Edward T.H. Yeh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

SUMO protease SENP1 is elevated in multiple carcinomas including prostate cancer (PCa). SENP1 exhibits carcinogenic properties; it promotes androgen receptordependent and -independent cell proliferation, stabilizes HIF1α, increases VEGF, and supports angiogenesis. However, mice expressing an androgen-responsive promoter driven SENP1-transgene (SENP1-Tg) develop high-grade prostatic intraepithelial neoplasia, but not carcinoma. We now show that tumor suppressive PTEN signaling is induced in SENP1-Tg to enhance prostate epithelial cell apoptosis. SENP1 blocks SUMO1-dependent ubiquitylation and degradation of PTEN. In the absence of SENP1, SUMO1-modified PTEN is sequestered in the cytosol, where binding to ubiquitin-E3 ligase WWP2 occurs. Concurrently, WWP2 is also SUMOylated, which potentiates its interaction with PTEN. Thus, SENP1 directs ubiquitin-E3-substrate association to control PTEN stability. PTEN serves as a barrier for SENP1-mediated prostate carcinogenesis as SENP1-Tg mice develop invasive carcinomas only after PTEN reduction. Hence, SENP1 modulates multiple facets of carcinogenesis and may serve as a target specifically for aggressive PTEN-deficient PCa.

Original languageEnglish
Pages (from-to)17651-17664
Number of pages14
JournalOncotarget
Volume8
Issue number11
DOIs
Publication statusPublished - Jan 1 2017
Externally publishedYes

Fingerprint

Transgenes
Prostatic Neoplasms
Carcinoma
Androgens
Prostate
Carcinogenesis
Prostatic Intraepithelial Neoplasia
Ubiquitin-Protein Ligases
Ubiquitination
Ubiquitin
Cytosol
Vascular Endothelial Growth Factor A
Peptide Hydrolases
Epithelial Cells
Cell Proliferation
Apoptosis
Neoplasms

Keywords

  • Prostate carcinogenesis
  • PTEN
  • SENP1
  • SUMO
  • WWP2

ASJC Scopus subject areas

  • Oncology

Cite this

Bawa-Khalfe, T., Yang, F. M., Ritho, J., Lin, H. K., Cheng, J., & Yeh, E. T. H. (2017). SENP1 regulates PTEN stability to dictate prostate cancer development. Oncotarget, 8(11), 17651-17664. https://doi.org/10.18632/oncotarget.13283

SENP1 regulates PTEN stability to dictate prostate cancer development. / Bawa-Khalfe, Tasneem; Yang, Feng Ming; Ritho, Joan; Lin, Hui Kuan; Cheng, Jinke; Yeh, Edward T.H.

In: Oncotarget, Vol. 8, No. 11, 01.01.2017, p. 17651-17664.

Research output: Contribution to journalArticle

Bawa-Khalfe, T, Yang, FM, Ritho, J, Lin, HK, Cheng, J & Yeh, ETH 2017, 'SENP1 regulates PTEN stability to dictate prostate cancer development', Oncotarget, vol. 8, no. 11, pp. 17651-17664. https://doi.org/10.18632/oncotarget.13283
Bawa-Khalfe, Tasneem ; Yang, Feng Ming ; Ritho, Joan ; Lin, Hui Kuan ; Cheng, Jinke ; Yeh, Edward T.H. / SENP1 regulates PTEN stability to dictate prostate cancer development. In: Oncotarget. 2017 ; Vol. 8, No. 11. pp. 17651-17664.
@article{413c06c03d834a8d96ac603d71101bd9,
title = "SENP1 regulates PTEN stability to dictate prostate cancer development",
abstract = "SUMO protease SENP1 is elevated in multiple carcinomas including prostate cancer (PCa). SENP1 exhibits carcinogenic properties; it promotes androgen receptordependent and -independent cell proliferation, stabilizes HIF1α, increases VEGF, and supports angiogenesis. However, mice expressing an androgen-responsive promoter driven SENP1-transgene (SENP1-Tg) develop high-grade prostatic intraepithelial neoplasia, but not carcinoma. We now show that tumor suppressive PTEN signaling is induced in SENP1-Tg to enhance prostate epithelial cell apoptosis. SENP1 blocks SUMO1-dependent ubiquitylation and degradation of PTEN. In the absence of SENP1, SUMO1-modified PTEN is sequestered in the cytosol, where binding to ubiquitin-E3 ligase WWP2 occurs. Concurrently, WWP2 is also SUMOylated, which potentiates its interaction with PTEN. Thus, SENP1 directs ubiquitin-E3-substrate association to control PTEN stability. PTEN serves as a barrier for SENP1-mediated prostate carcinogenesis as SENP1-Tg mice develop invasive carcinomas only after PTEN reduction. Hence, SENP1 modulates multiple facets of carcinogenesis and may serve as a target specifically for aggressive PTEN-deficient PCa.",
keywords = "Prostate carcinogenesis, PTEN, SENP1, SUMO, WWP2",
author = "Tasneem Bawa-Khalfe and Yang, {Feng Ming} and Joan Ritho and Lin, {Hui Kuan} and Jinke Cheng and Yeh, {Edward T.H.}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.13283",
language = "English",
volume = "8",
pages = "17651--17664",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "11",

}

TY - JOUR

T1 - SENP1 regulates PTEN stability to dictate prostate cancer development

AU - Bawa-Khalfe, Tasneem

AU - Yang, Feng Ming

AU - Ritho, Joan

AU - Lin, Hui Kuan

AU - Cheng, Jinke

AU - Yeh, Edward T.H.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - SUMO protease SENP1 is elevated in multiple carcinomas including prostate cancer (PCa). SENP1 exhibits carcinogenic properties; it promotes androgen receptordependent and -independent cell proliferation, stabilizes HIF1α, increases VEGF, and supports angiogenesis. However, mice expressing an androgen-responsive promoter driven SENP1-transgene (SENP1-Tg) develop high-grade prostatic intraepithelial neoplasia, but not carcinoma. We now show that tumor suppressive PTEN signaling is induced in SENP1-Tg to enhance prostate epithelial cell apoptosis. SENP1 blocks SUMO1-dependent ubiquitylation and degradation of PTEN. In the absence of SENP1, SUMO1-modified PTEN is sequestered in the cytosol, where binding to ubiquitin-E3 ligase WWP2 occurs. Concurrently, WWP2 is also SUMOylated, which potentiates its interaction with PTEN. Thus, SENP1 directs ubiquitin-E3-substrate association to control PTEN stability. PTEN serves as a barrier for SENP1-mediated prostate carcinogenesis as SENP1-Tg mice develop invasive carcinomas only after PTEN reduction. Hence, SENP1 modulates multiple facets of carcinogenesis and may serve as a target specifically for aggressive PTEN-deficient PCa.

AB - SUMO protease SENP1 is elevated in multiple carcinomas including prostate cancer (PCa). SENP1 exhibits carcinogenic properties; it promotes androgen receptordependent and -independent cell proliferation, stabilizes HIF1α, increases VEGF, and supports angiogenesis. However, mice expressing an androgen-responsive promoter driven SENP1-transgene (SENP1-Tg) develop high-grade prostatic intraepithelial neoplasia, but not carcinoma. We now show that tumor suppressive PTEN signaling is induced in SENP1-Tg to enhance prostate epithelial cell apoptosis. SENP1 blocks SUMO1-dependent ubiquitylation and degradation of PTEN. In the absence of SENP1, SUMO1-modified PTEN is sequestered in the cytosol, where binding to ubiquitin-E3 ligase WWP2 occurs. Concurrently, WWP2 is also SUMOylated, which potentiates its interaction with PTEN. Thus, SENP1 directs ubiquitin-E3-substrate association to control PTEN stability. PTEN serves as a barrier for SENP1-mediated prostate carcinogenesis as SENP1-Tg mice develop invasive carcinomas only after PTEN reduction. Hence, SENP1 modulates multiple facets of carcinogenesis and may serve as a target specifically for aggressive PTEN-deficient PCa.

KW - Prostate carcinogenesis

KW - PTEN

KW - SENP1

KW - SUMO

KW - WWP2

UR - http://www.scopus.com/inward/record.url?scp=85015189227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015189227&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13283

DO - 10.18632/oncotarget.13283

M3 - Article

C2 - 27852060

AN - SCOPUS:85015189227

VL - 8

SP - 17651

EP - 17664

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -